Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06752759
PHASE3

Nebulized Ketamine for the Treatment of Major Depressive Disorder

Sponsor: Theresa Jacob, PhD, MPH

View on ClinicalTrials.gov

Summary

This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.

Official title: Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting: A Midazolam-controlled Randomized Controlled Trial

Key Details

Gender

All

Age Range

18 Years - 88 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2024-10-16

Completion Date

2027-09-30

Last Updated

2026-04-24

Healthy Volunteers

No

Interventions

DRUG

nebulized ketamine

The formulation of the study drug is administered via nebulizer in which the participants inhales the study drug. The dosage is calculated by body weight (1.5mg/kg).

DRUG

nebulized midazolam

The formulation of the active comparator drug is administered via nebulizer in which the participant inhales the study drug. The dosage is calculated by body weight (0.03mg/kg).

Locations (1)

Maimonides Medical Center

Brooklyn, New York, United States